Clinical trials: sponsored by Merck Sharp & Dohme LLC
Neurofibromatosis Type 1
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints.
- Trial name
- SPRINKLE (NCT05309668)
- Testing
- Selumetinib granule formulation, Selumetinib capsule formulation
- Where
- 16 sites in United States, Germany and 5 more
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Melanoma, Uveal
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
- Trial name
- NCT05308901
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
This phase I/II trial tests the safety and effectiveness of receiving external beam radiation therapy (EBRT) and brachytherapy along with chemotherapy, consisting of cisplatin and paclitaxel, and immunotherapy, consisting of…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8
- Trial name
- NCT06543576
- Testing
- Bevacizumab, Biospecimen Collection, Brachytherapy
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Invasive Fungal Infection
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants <2 years of age with invasive fungal infection…
- Trial name
- NCT04665037
- Testing
- Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kg
- Where
- 26 sites in United States, Belgium and 8 more
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Urothelial Carcinoma, Oral Drug Administration
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma.
- Conditions
- Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
- Trial name
- NCT05929235
- Testing
- FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Flare Therapeutics Inc.
Breast Cancer, Insomnia
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
Investigators propose a double-blind, placebo-controlled trial evaluating the use of the use of Suvorexant in breast cancer survivors on selective estrogen receptor modulators or aromatase inhibitors with sleep disturbance to…
- Trial name
- NCT06162663
- Testing
- Suvorexant Tablets
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Medical University of South Carolina
Gastric Cancer, Gastroesophageal Junction Cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC)…
- Trial name
- NCT06731478
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab
- Where
- 250 sites in United States, Argentina and 24 more
- Volunteers
- 726 people
- Sponsor
- Daiichi Sankyo
Vaccination
"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake
This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing HPV vaccination.
- Trial name
- NCT06587243
- Testing
- Informational Animation Video, Personal Narrative Video
- Where
- United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Systemic Lupus Erythematosus
Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus.
- Trial name
- NCT06161116
- Testing
- MK-6194
- Where
- 127 sites in United States, Argentina and 15 more
- Volunteers
- 149 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophagogastric Adenocarcinoma
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
The study is an open-label, single arm, multicenter phase II trial investigating the clinical activity of a perioperative therapy consisting of a combination of pembrolizumab, trastuzumab and FLOT, followed by pembrolizumab plus…
- Trial name
- NCT05504720
- Testing
- Pembrolizumab, Trastuzumab, FLOT
- Where
- 13 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Metastatic Solid Tumors, Advanced Solid Tumors
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically…
- Trial name
- NCT05853367
- Testing
- MK-0472, Pembrolizumab, MK-1084
- Where
- 25 sites in United States, Canada and 5 more
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Carriage
Pneumococcal Carriage Duration
Streptococcus pneumoniae (SPN) remains a leading cause of respiratory disease in young children despite widespread vaccination. Understanding the duration of pneumococcal carriage, patterns of co-colonization, and the influence…
- Trial name
- NCT07748832
- Testing
- Oropharyngeal (OP) swab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Lymphoma, Histiocytic Sarcoma
Pembrolizumab in Neoplasms or Lymphomas
This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembrolizumab
- Conditions
- Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
- Trial name
- NCT03316573
- Testing
- Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Small Cell Lung Cancer
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
- Trial name
- IDeate-Lung02 (NCT06203210)
- Testing
- Ifinatamab deruxtecan, Topotecan, Amrubicin
- Where
- 229 sites in United States, Australia and 21 more
- Volunteers
- 540 people
- Sponsor
- Daiichi Sankyo
Ovarian Carcinosarcoma, Uterine Carcinosarcoma
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression.
- Trial name
- EPOCH (NCT05619913)
- Testing
- Eribulin Mesylate, Pembrolizumab
- Where
- 6 sites in Australia, Canada and 1 more
- Volunteers
- 13 people
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
Lung Cancer
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
The purpose of this study is to test the safety of a combination of three drugs, pembrolizumab, guadecitabine and mocetinostat. Pembrolizumab is a drug given by vein and all patients will receive the same dose.
- Trial name
- NCT03220477
- Testing
- Pembrolizumab, Guadecitabine, Mocetinostat
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Muscle Invasive Bladder Urothelial Carcinoma
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and cystoscopy with TURBT of any visible tumor and/or…
- Trial name
- NCT06809140
- Testing
- Enfortumab vedotin, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Matthew Galsky
Metastatic Renal Cell Carcinoma
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including…
- Trial name
- ODYSSEY RCC (NCT04919122)
- Where
- 14 sites in United States
- Volunteers
- 468 people
- Sponsor
- Duke University
Cancer of Head and Neck, Head and Neck Cancer
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs)…
- Conditions
- Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- NCT02296684
- Testing
- MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Washington University School of Medicine
Pancreatic Ductal Adenocarcinoma
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma…
- Trial name
- NCT05132504
- Testing
- Pembrolizumab, Folfirinox
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.